Takeda Pharmaceutical Company Limited | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (23)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Article By: ChinaBio® Today
Saturday, January 13, 2024 1:20 PM EDT
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion.
In this article: GSK, JNJ, NVS, BAYRY, BNTX, PRAX, AMAM, HLVX Also: TAK
Read
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
Article By: ChinaBio® Today
Saturday, April 8, 2023 2:20 PM EDT
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up to $1.5 billion in milestone payments.
In this article: PFE, BNTX Also: MRK, VRNA, AMGN, HCM, TAK, SBHMY
Read
Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million
Article By: ChinaBio® Today
Saturday, March 25, 2023 2:19 PM EDT
HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product for $10 million upfront and $10 million in equity.
In this article: BHVN Also: SBMFF, TAK, CNTB
Read
NeurAxis: Should You Buy This IPO?
Article By: Avisol Capital Partners
Wednesday, February 8, 2023 12:14 PM EDT
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype.
In this article: NRXS Also: MASI, BMY, PFE, ARNA, AMGN, GILD, ABBV, TAK
Read
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
Article By: Moon Kil Woong
Monday, February 6, 2023 4:14 PM EDT
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio.
In this article: NRXS Also: ABBV, BMY, AMGN, ARNA, GILD, PFE, TAK
Read
All Posts

Latest Tweets for $TAK

No tweets yet!

PARTNER HEADLINES